Thiogenesis Announces Grant of Stock Options

Company Overview - Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company based in San Diego, California, publicly traded on the TSX Venture Exchange and OTCQX [2] - The company is focused on developing sulfur-containing prodrugs aimed at treating serious pediatric diseases with unmet medical needs [2] Product Development - Thiogenesis' lead product candidate, TTI-0102, is currently in an active Phase 2 clinical trial for Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS) [2] - The company is planning to initiate clinical trials for additional conditions including Leigh syndrome, Rett syndrome, and pediatric MASH [2] Recent Corporate Actions - On June 11, 2025, the company's board of directors approved a grant of 400,000 common share purchase options at an exercise price of $0.77 to two directors [1] - The options will vest at a rate of 25% every six months and will expire on June 11, 2030 [1]